Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. I-Mab
  6. News
  7. Summary
    IMAB   US44975P1030

I-MAB

(IMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

I Mab : Says Plonmarlimab Demonstrated Therapeutic Potential in Severe COVID-19

08/11/2021 | 09:08am EDT


ę MT Newswires 2021
All news about I-MAB
12:30pI-Mab Enters Into Partnership With China's Sinopharm to Distribute Its Products
MT
08:01aI-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its I..
PR
10/25I-MAB : to set up new Translational Medicine and Formulation Research site in San Diego
AQ
10/22I MAB : to Open Translational Medicine Research Site in San Diego
MT
10/22I-MAB : Expands U.S. Footprint with New R&D Site in San Diego
PR
10/22I-Mab Expands U.S. Footprint with New R&D Site in San Diego
CI
10/19I MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PU
10/18I MAB : Gets IND Approval to Conduct Mid-Stage Cancer Drug Trial in China
MT
10/18I-MAB : Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinati..
PR
10/18I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combinat..
CI
More news
Analyst Recommendations on I-MAB
More recommendations
Financials (USD)
Sales 2021 73,7 M - -
Net income 2021 -216 M - -
Net cash 2021 587 M - -
P/E ratio 2021 -28,5x
Yield 2021 -
Capitalization 4 887 M 4 887 M -
EV / Sales 2021 58,4x
EV / Sales 2022 22,3x
Nbr of Employees 228
Free-Float 98,7%
Chart I-MAB
Duration : Period :
I-Mab Technical Analysis Chart | IMAB | US44975P1030 | MarketScreener
Technical analysis trends I-MAB
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 63,50 $
Average target price 96,57 $
Spread / Average Target 52,1%
EPS Revisions
Managers and Directors
Hua Qiong Shen Chief Executive Officer & Director
Zheru Zhang President & Director
Jielun Zhu Chief Financial Officer & Director
Jing Wu Zang Chairman
Lili Qian Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
I-MAB43.46%5 206
JOHNSON & JOHNSON5.32%431 938
ROCHE HOLDING AG15.61%338 364
NOVO NORDISK A/S59.69%243 351
PFIZER, INC.17.22%241 929
ELI LILLY AND COMPANY47.15%222 158